PPARγ agonists, such as pioglitazone, can induce NASH remission in patients with noncirrhotic NASH, regardless of the presence or absence of T2D, indirectly proving the pathogenic role of IR in NASH [47]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.